Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

235.60DKK
16 Apr 2014
Price Change (% chg)

kr.4.90 (+2.12%)
Prev Close
kr.230.70
Open
kr.232.10
Day's High
kr.236.30
Day's Low
kr.231.80
Volume
2,677,969
Avg. Vol
3,521,799
52-wk High
kr.265.30
52-wk Low
kr.169.60

NOVOb.CO

Chart for NOVOb.CO

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition,... (more)

Overall

Beta: 0.98
Market Cap (Mil.): kr.521,280.09
Shares Outstanding (Mil.): 2,212.56
Dividend: 4.50
Yield (%): 1.91

Financials

  NOVOb.CO Industry Sector
P/E (TTM): 25.20 32.99 33.14
EPS (TTM): 9.35 -- --
ROI: 55.88 19.69 18.95
ROE: 60.54 20.38 19.71
Search Stocks

Novo Nordisk sees chance of U.S. Tresiba launch before rival products

COPENHAGEN, March 20 - Novo Nordisk should still be able to introduce its long-acting insulin Tresiba on the U.S. market before rival products, despite being hit by a delay, the CEO of the Danish pharmaceutical company said on Thursday.

20 Mar 2014

Novo Nordisk's IT unit appoints advisers for possible IPO

COPENHAGEN, March 18 - NNIT, the information technology unit of Danish pharmaceuticals company Novo Nordisk , said on Tuesday it had appointed Morgan Stanley and Danske Bank to advise on the possibility of a separate listing.

18 Mar 2014

UPDATE 1-NORDIC STOCKS-Factors to watch on March 6

(Adds Novo factor) The following stocks may be affected by newspaper reports and other factors on Thursday:

06 Mar 2014

Lilly weekly diabetes drug as effective as market leader Victoza-study

- An experimental once-weekly medicine for type 2 diabetes developed by Eli Lilly and Co proved as effective in lowering blood sugar as Victoza from Danish drugmaker Novo Nordisk in an eagerly anticipated late stage study.

25 Feb 2014

UPDATE 1-Lilly weekly diabetes drug as effective as market leader Victoza-study

Feb 25 - An experimental once-weekly medicine for type 2 diabetes developed by Eli Lilly and Co proved as effective in lowering blood sugar as Victoza from Danish drugmaker Novo Nordisk in an eagerly anticipated late stage study.

25 Feb 2014

Lilly weekly diabetes drug succeeds vs market leader Victoza -study

Feb 25 - An experimental once-weekly medicine for type 2 diabetes developed by Eli Lilly and Co proved as effective in lowering blood sugar as Victoza from Danish drugmaker Novo Nordisk in an eagerly anticipated late stage study.

25 Feb 2014

BRIEF-Innate Pharma buys rights to drug from Novo Nordisk

Feb 5 - Innate Pharma SA : * Buys full rights to anti-nkg2a checkpoint inhibitor from Novo Nordisk

05 Feb 2014

UPDATE 1-Israel's Oramed a step closer in race for first insulin pill

* Phase IIa trial meets all primary and secondary endpoints

30 Jan 2014

Denmark's Novo Nordisk sees copycat drugs hitting sales

COPENHAGEN - Novo Nordisk, the world's largest insulin producer, raised its 2014 outlook by less than investors had hoped for saying it expected sales to be hit by contract losses in the United States and competition from cheaper generic drugs.

30 Jan 2014

UPDATE 2-Denmark's Novo Nordisk sees copycat drugs hitting sales

* Q4 profit 7.35 mln crowns vs 7.73 bln forecast (Adds comments from CEO, CFO and analysts, details, background, share price)

30 Jan 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: TheStreet.com Ratings
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks